Skip to content
Collaborators Login
  • Home
  • Who We Are
    • About Us
  • What We Do
    • Programs & Services
  • BioIntelligence
  • News
    • Press Releases
    • Publications
    • Events
  • Contact Us

Koscik RL, Betthauser TJ, Jonaitis EM, et al. Amyloid duration is associated with preclinical cognitive decline and tau PET. Alzheimers Dement (Amst). 2020;12(1):e12007. Doi: 10.1002/dad2.12007.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085284/

Post navigation

Previous: Therriault J, Benedet AL, Pascoal TA, et al. Association of apolipoprotein E ε4 with medial temporal tau independent of amyloid-β. JAMA Neurol. 2020; 77(4):470-479. Doi: 10.1001/jamaneurol.2019.4421.
Next: Betthauser TJ, Koscik RL, Jonaitis EM, et al. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age. Brain. 2020; 143(1):320-335. Doi: 10.1093/brain/awz378.

Recent Posts

  • Enigma Biomedical – USA Announces Collaboration with Alamar Biosciences to Advance the Field of Diagnostics for Neurodegenerative Diseases
  • Enigma Biomedical USA Announces Formation of Scientific Advisory Board
  • Enigma Biomedical USA and the University of Wisconsin
  • Enigma Biomedical USA, Inc. Announces a Collaboration to Apply Novel 4R PET Imaging Biomarkers to CTE Research

Recent Comments

    Archives

    • February 2026

    Categories

    • PRESS RELEASE

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    308 N. Peters Road Suite #201
    Knoxville, TN 37922

    customercare@enigmabiomedicalgroup.com

    © Copyright 2026 Enigma Biomedical Inc. All Rights Reserved.

    • Home
    • Who We Are
      • About Us
    • What We Do
      • Programs & Services
    • BioIntelligence
    • News
      • Press Releases
      • Publications
      • Events
    • Contact Us